JAZZ Jazz Pharmaceuticals plc

  1. Stocks
  2. Healthcare
  3. NASDAQ: JAZZ

Price (delayed)

$230.25

Market cap

$14.45B

P/E Ratio

489.89

Dividend/share

N/A

EPS

$0.47

Enterprise value

$18B

?
Relative Growth: Rel. Growth: 42
Relative Strength: Rel. Strength: 87
Relative Valuation: Rel. Valuation: 20
Relative Profitability: Rel. Profitability: 39

Jazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration ...

Highlights
The revenue has grown by 9% YoY and by 4% from the previous quarter
Jazz Pharmaceuticals's equity has increased by 9% YoY and by 4.9% from the previous quarter
The company's EPS has surged by 108% QoQ but it has shrunk by 94% YoY
Jazz Pharmaceuticals's net income has surged by 108% QoQ but it has shrunk by 94% YoY
Sector: Healthcare
Industry: Biotechnology
Peers: NVS TEVA PRGO

Key stats

What are the main financial stats of JAZZ

JAZZ stock price

How has the Jazz Pharmaceuticals stock price performed over time
Intraday
1.92%
1 week
1.49%
1 month
-3.99%
1 year
115.67%
YTD
35.44%
QTD
21.79%

Financial performance

How have Jazz Pharmaceuticals's revenue and profit performed over time
Revenue
$4.44B
Gross profit
$3.91B
Operating income
-$37.75M
Net income
$29.49M
Gross margin
88%
Net margin
0.7%
Jazz Pharmaceuticals's net income has surged by 108% QoQ but it has shrunk by 94% YoY
The company's net margin has surged by 108% QoQ but it has shrunk by 94% YoY
The operating income has dropped by 106% year-on-year but it has surged by 91% since the previous quarter
JAZZ's operating margin has dropped by 106% year-on-year but it has soared by 91% since the previous quarter

Price vs fundamentals

How does JAZZ's price correlate with its fundamentals

Growth

What is Jazz Pharmaceuticals's growth rate over time

Valuation

What is Jazz Pharmaceuticals stock price valuation
JAZZ P/E details
P/E
489.89
P/B
3.13
P/S
3.21
EV/EBIT
N/A
EV/EBITDA
26.67
EV/Sales
4.06
The company's EPS has surged by 108% QoQ but it has shrunk by 94% YoY
The price to book (P/B) is 42% higher than the last 4 quarters average of 2.2 and 36% higher than the 5-year quarterly average of 2.3
Jazz Pharmaceuticals's equity has increased by 9% YoY and by 4.9% from the previous quarter
The price to sales (P/S) is 53% more than the last 4 quarters average of 2.1 and 40% more than the 5-year quarterly average of 2.3
The revenue has grown by 9% YoY and by 4% from the previous quarter

Efficiency

How efficient is Jazz Pharmaceuticals business performance
The company's return on assets has surged by 110% QoQ but it has shrunk by 93% YoY
The return on equity has surged by 108% since the previous quarter but it has dropped by 94% year-on-year
JAZZ's ROIC has shrunk by 107% YoY but it has soared by 92% QoQ
The company's return on sales has shrunk by 106% YoY but it has surged by 91% QoQ

Dividends

What is JAZZ's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for JAZZ.

Financial health

How did Jazz Pharmaceuticals financials performed over time
The total assets is 62% greater than the total liabilities
The company's current ratio fell by 40% YoY but it rose by 10% QoQ
Jazz Pharmaceuticals's quick ratio has decreased by 38% YoY but it has increased by 13% from the previous quarter
The company's debt is 19% higher than its equity
Jazz Pharmaceuticals's equity has increased by 9% YoY and by 4.9% from the previous quarter
Jazz Pharmaceuticals's debt to equity has decreased by 8% YoY and by 4.8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.